PRALUENT 75 MG
ALIROCUMAB : 75 MG · DIN 02453819 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is PRALUENT?
PRALUENT 75 MG contains ALIROCUMAB : 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02453819, held by SANOFI-AVENTIS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 18-May-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRALUENT used for?
Prevention of cardiovascular events in adults with established CV disease; reduction of LDL-C in adults with primary hyperlipidemia (heterozygous familial and non-familial).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02453819 |
|---|---|
| Brand name | PRALUENT |
| Generic / active ingredient | ALIROCUMAB : 75 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 75 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | C10AX14 ALIROCUMAB |
| AHFS class | 24:06.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-May-2016 |
| Original market date | 2016-05-18 00:00:00 |
How is it administered?
Starting dose: 75 mg subcutaneously every 2 weeks or 300 mg every 4 weeks. Measure LDL-C within 4-8 weeks; may adjust to maximum 150 mg every 2 weeks if response is inadequate.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store in refrigerator (implied by instructions to remove 30-45 mins before use to reach room temperature). (Note: Specific temp range not in snippet).
How is it supplied?
75 or 150 mg PFP: 1, 2, or 6 per carton. 300 mg PFP: 1 or 3 per carton. Supplied in Type 1 clear glass syringes.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious hypersensitivity reactions (angioedema, rash, vasculitis) reported. Discontinue if serious reactions occur. Long-term effects of very low LDL-C are unknown.
What can be used instead?
Other Canadian products sharing ATC code C10AX14 ALIROCUMAB. 3 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PRALUENT | 150 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02453835 |
| PRALUENT | 300 MG / 2 ML | SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02547732 |
| PRALUENT | 150 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02453762 |
| PRALUENT | 75 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02453754 |
Who else supplies ALIROCUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALIROCUMAB appears in 44 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.